Integrated BioPharma Statistics
Total Valuation
Integrated BioPharma has a market cap or net worth of 11.51 million. The enterprise value is 10.80 million.
| Market Cap | 11.51M |
| Enterprise Value | 10.80M |
Important Dates
The next estimated earnings date is Tuesday, February 11, 2025.
| Earnings Date | Feb 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Integrated BioPharma has 30.30 million shares outstanding. The number of shares has increased by 3.64% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 30.30M |
| Shares Change (YoY) | +3.64% |
| Shares Change (QoQ) | -0.17% |
| Owned by Insiders (%) | 15.36% |
| Owned by Institutions (%) | 0.07% |
| Float | 9.44M |
Valuation Ratios
The trailing PE ratio is 26.60.
| PE Ratio | 26.60 |
| Forward PE | n/a |
| PS Ratio | 0.22 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.06, with an EV/FCF ratio of -38.03.
| EV / Earnings | 25.12 |
| EV / Sales | 0.21 |
| EV / EBITDA | 5.06 |
| EV / EBIT | 13.59 |
| EV / FCF | -38.03 |
Financial Position
The company has a current ratio of 3.04, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.04 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | -5.49 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 2.24% and return on invested capital (ROIC) is 2.34%.
| Return on Equity (ROE) | 2.24% |
| Return on Assets (ROA) | 1.88% |
| Return on Capital (ROIC) | 2.34% |
| Revenue Per Employee | 347,068 |
| Profits Per Employee | 2,925 |
| Employee Count | 147 |
| Asset Turnover | 1.93 |
| Inventory Turnover | 4.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +72.73% in the last 52 weeks. The beta is 0.59, so Integrated BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +72.73% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.25 |
| Relative Strength Index (RSI) | 59.03 |
| Average Volume (20 Days) | 10,322 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.12 |
Income Statement
In the last 12 months, Integrated BioPharma had revenue of 51.02 million and earned 430,000 in profits. Earnings per share was 0.01.
| Revenue | 51.02M |
| Gross Profit | 4.42M |
| Operating Income | 795,000 |
| Pretax Income | 818,000 |
| Net Income | 430,000 |
| EBITDA | 1.13M |
| EBIT | 795,000 |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 2.27 million in cash and 1.56 million in debt, giving a net cash position of 713,000 or 0.02 per share.
| Cash & Cash Equivalents | 2.27M |
| Total Debt | 1.56M |
| Net Cash | 713,000 |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 19.55M |
| Book Value Per Share | 0.65 |
| Working Capital | 12.28M |
Cash Flow
In the last 12 months, operating cash flow was 287,000 and capital expenditures -571,000, giving a free cash flow of -284,000.
| Operating Cash Flow | 287,000 |
| Capital Expenditures | -571,000 |
| Free Cash Flow | -284,000 |
| FCF Per Share | -0.01 |
Margins
Gross margin is 8.67%, with operating and profit margins of 1.56% and 0.84%.
| Gross Margin | 8.67% |
| Operating Margin | 1.56% |
| Pretax Margin | 1.60% |
| Profit Margin | 0.84% |
| EBITDA Margin | 2.21% |
| EBIT Margin | 1.56% |
| FCF Margin | n/a |
Dividends & Yields
Integrated BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.64% |
| Shareholder Yield | -3.64% |
| Earnings Yield | 3.73% |
| FCF Yield | -2.47% |
Stock Splits
The last stock split was on July 2, 1996. It was a reverse split with a ratio of 0.25.
| Last Split Date | Jul 2, 1996 |
| Split Type | Reverse |
| Split Ratio | 0.25 |
Scores
Integrated BioPharma has an Altman Z-Score of 1.53. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.53 |
| Piotroski F-Score | n/a |